USE AND CLINICAL EXPERIENCE OF Dolutegravir/Abacavir/Lamivudina in a Tertiary Hospital

S. Vicente Sánchez, L. Menéndez Naranjo, M. Valderrey Pulido, MM. Ruiz Jimenez, JI. García Soler, . A. de La Rubia Nieto. Hospital Clínico Universitario Virgen de la Arrixaca

BACKGROUND
The new co-formulated drugs for HIV have made great strides in treating the disease and have achieved excellent health outcomes in patients.

METHODS
- Retrospective observational study of all patients who started DTG / ABC / 3TC in our hospital.
- The variables included were: age, gender, number of previous antiretroviral regimens, patient type (naïve, pre-treated), reason of prescription (treatment initiation, switch strategies and virological failure) and viral load (VL) pretreatment, after 4 and 12 weeks.

RESULTS
- A total of 33 patients started the treatment with DTG / ABC / 3TC, 3 of them discontinued it.
- The mean age of patients was 51 (± 13.4) years and 75.7% were men.
- 81.9% of patients had been previously treated with at least one antiretroviral regimen.

TREATMENT EFFECTIVENESS

<table>
<thead>
<tr>
<th>VL</th>
<th>NAIVE PATIENTS AFTER 12 WEEKS OF TREATMENT</th>
<th>PATIENTS WITH VIROLOGICAL FAILURE</th>
<th>REST OF PATIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;50 COPIES/ML</td>
<td>-</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>&lt;20 COPIES/ML</td>
<td>3</td>
<td>2</td>
<td>9</td>
</tr>
<tr>
<td>UNDETECTABLE VL</td>
<td>3</td>
<td>2</td>
<td>11</td>
</tr>
<tr>
<td>INCREASED VL AT WEEK 12</td>
<td>-</td>
<td>-</td>
<td>2</td>
</tr>
</tbody>
</table>

Reasons of prescription (%)
- Naïve patients: 18.1%
- Virologic failure: 15.1%
- Switch strategies: 66.8%

CONCLUSIONS
- DTG / ABC / 3TC was used principally in pretreated patients and switch strategies was the main reason of prescription.
- In most patients, low or undetectable viral loads were obtained, thus achieving good disease control.